Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 13, 2014, Pages 1879-1882

  Marconi, Stefano ^a   Zwingers, T ^b  

^a CHIESI FARMACEUTICI S P A   (Italy)

^b CROS DE GmbH A CROS NT Group company ^*  (Germany)

Author keywords

Parkinson's disease; Rasagiline; Selegiline

Indexed keywords

BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; LEVODOPA; PLACEBO; RASAGILINE; SELEGILINE; TOCOPHEROL; ANTIPARKINSON AGENT; INDAN DERIVATIVE; MONOAMINE OXIDASE INHIBITOR;

COMPARATIVE STUDY; CONFIDENCE INTERVAL; DRUG EFFICACY; FOREST PLOT; HUMAN; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STANDARDIZED MEAN DIFFERENCE; STATISTICAL ANALYSIS; STATISTICAL PARAMETERS; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE; TREATMENT OUTCOME;

ANTIPARKINSON AGENTS; HUMANS; INDANS; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELEGILINE; TREATMENT OUTCOME;

EID: 84926106645     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Rascol O, Lozano A, Stern M, Poewe W. Milestones In Parkinson's Disease Therapeutics. Mov Disord 2011; 26: 1072-1082
2. Schapira Ah. Monoamine Oxidase B Inhibitors For The Treatment Of Parkinson's Disease: A Review Of Symptomatic And Potential Disease-Modifying Effects. Cns Drugs 2011; 25: 1061-1071
3. Weinreb O, Amit T, Bar-Am O, Youdim Mb. Rasagiline: A Novel Anti-Parkinsonian Monoamine Oxidase-B Inhibitor With Neuroprotective Activity. Prog Neurobiol 2010; 92: 330-344
4. Fabbrini G, Abbruzzese G, Marconi S, Zappia M. Selegiline: A Reappraisal Of Its Role In Parkinson Disease. Clin Neuropharmacol 2012; 35: 134-140
5. Stowe R, Ives N, Clarke Ce, Handley K, Furmston A, Deane K, Van Hilten Jj, Wheatley K, Gray R. Metaanalysis Of The Comparative Efficacy And Safety Of Adjuvant Treatment To Levodopa In Later Parkinson's Disease. Mov Disord 2011; 26: 587-598
6. Jost Wh, Friede M, Schnitker J. Indirect Metaanalysis Of Randomised Placebo-Controlled Clinical Trials On Rasagiline And Selegiline In The Symptomatic Treatment Of Parkinson's Disease. Basal Ganglia 2012; 2: S17-S26
7. Movement Disorder Society Task Force On Rating Scales For Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (Updrs): Status And Recommendations. Mov Disord 2003; 18: 738-750
8. Rascol O. "Disease-Modification" Trials In Parkinson Disease: Target Populations, Endpoints And Study Design. Neurology 2009; 72(7 Suppl): S51-58
9. Olanow Cw, Hauser Ra, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J. The Effect Of Deprenyl And Levodopa On The Progression Of Parkinson's Disease. Ann Neurol 1995; 38: 771-777
10. Shults Cw. Effect Of Selegiline (Deprenyl) On The Progression Of Disability In Early Parkinson's Disease. Parkinson Study Group. Acta Neurol Scand Suppl 1993; 146: 36-42
11. Larsen Jp, Boas J, Erdal Je. Does Selegiline Modify The Progression Of Early Parkinson's Disease? Results From A Five-Year Study. The Norwegian-Danish Study Group. Eur J Neurol 1999; 6: 539-547
12. Palhagen S, Heinonen Eh, HäGglund J, Kaugesaar T, Kontants H, MäKi-Ikola O, Palm R, Turunen J. Selegiline Delays The Onset Of Disability In De Novo Parkinsonian Patients. Swedish Parkinson Study Group. Neurology 1998; 51: 520-525
13. Allain H, Pollak P, Neukirch Hc. Symptomatic Effect Of Selegiline In De Novo Parkinsonian Patients. The French Selegiline Multicenter Trial. Mov Disord 1993; 8(Suppl 1): S36-40
14. Rabey Jm, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R, Djaldetti R, Klein C, Berecz G; Rasagiline Study Group. Rasagiline Mesylate, A New Mao-B Inhibitor For The Treatment Of Parkinson's Disease: A Double-Blind Study As Adjunctive Therapy To Levodopa. Clin Neuropharmacol 2000; 23: 324-330
15. Parkinson Study Group. A Controlled Trial Of Rasagiline In Early Parkinson Disease: The Tempo Study. Arch Neurol 2002; 59: 1937-1943
16. Stern Mb, Marek Kl, Friedman J, Hauser Ra, Lewitt Pa, Tarsy D, Olanow Cw. Double-Blind, Randomized, Controlled Trial Of Rasagiline As Monotherapy In Early Parkinson's Disease Patients. Mov Disord 2004; 19: 916-923
17. Olanow Cw, Rascol O, Hauser R, Feigin Pd, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; Adagio Study Investigators. A Double-Blind, Delayed-Start Trial Of Rasagiline In Parkinson's Disease. N Engl J Med 2009; 361: 1268-1278.